期刊文献+

晚期胰腺癌两种化疗方案的药物经济学对比研究 被引量:2

The drug-economic ananlysis of two chemotherapy regimens for advanced pancreatic cancer
下载PDF
导出
摘要 目的比较吉西他滨联合替吉奥(GS)、吉西他滨联合白蛋白紫杉醇(AG)治疗晚期胰腺癌的临床效果和药物成本。方法收集2018年6月~2020年6月治疗的晚期胰腺癌患者作为研究对象,选择吉西他滨联合替吉奥(GS)、吉西他滨联合白蛋白紫杉醇(AG)治疗患者各56例作为研究对象,比较两组患者的治疗效果、不良反应发生率以及药物成本。结果两组患者中,GS组的客观有效率(ORR)为8.93%,AG组ORR为21.43%,GS组的疾病控制率(DCR)为71.43%,AG组DCR为83.93%,差异均无统计学意义。AG化疗方案总药费用为(20191.97±634.72)元/周期,成本-效果比为942.23;GS化疗方案总药费用为(5933.58±322.56)元/周期,成本-效果比为664.45,AG化疗方案成本-效果比显著大于GS化疗方案。两组患者不良反应发生率间差异无统计学意义。结论AG、GS治疗晚期胰腺癌,临床效果和不良反应发生率间差异无统计学意义,但GS较AG治疗方案成本-效果比显著降低,可能更具经济效益。 Objective To compare the clinical effects and cost of drugs in the treatment of advanced pancreatic cancer with two chemotherapy regimens-gemcitabine combined with tegafur(GS)and gemcitabine combined with abraxane(AG).Methods The patients with advanced pancreatic cancer who were treated from June 2018 to June 2020 were collected as the objects.Patients received treatment with two chemotherapy regimens-gemcitabine combined with tegafur(GS)or gemcitabine combined with abraxane(AG),56 patients in each group.The effect of treatment,the accidence of adverse reaction and the cost of drug in the two groups were compared.Results Among the two groups of patients,the objective response rate(ORR)of the GS group was 8.93%,the ORR of the AG group was 21.43%,the disease control rate(DCR)of the GS group was 71.43%,and the DCR of the AG group was 83.93%,and there was no significant difference.The total cost of drug of AG chemotherapy is(20191.97±634.72)yuan/cycle,the cost-effectiveness ratio is 942.23;and the total cost of GS chemotherapy program is(5933.58±322.56)yuan/cycle,The cost-effectiveness ratio is 664.45.The cost of AG chemotherapy is significantly greater than that of GS chemotherapy.There was no significant difference in the incidence of adverse reactions between the two groups.Conclusion There is no significant difference between the clinical effects and the incidence of adverse reactions between AG and GS in the treatment of advanced pancreatic cancer.However,the cost of GS is significantly lower than that of AG,and it may be more economical.
作者 杨若朦 谢毓华 辛乐 杨晓莉 赵丽 YANG Ruo-meng;XIE Yu-hua;XIN Le(Xi'an University,Xi'an 710065,China;不详)
出处 《中国处方药》 2023年第3期136-139,共4页 Journal of China Prescription Drug
基金 陕西省重点研发计划(2019SF-277)。
关键词 晚期胰腺癌 吉西他滨 替吉奥 白蛋白紫杉醇 Advanced pancreatic cancer Gemcitabine Tegafur Abraxane
  • 相关文献

参考文献1

二级参考文献4

共引文献346

同被引文献21

引证文献2

二级引证文献1

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部